Evidence map›Paper›PMID 29042776›Full record

ReviewInternational journal of nanomedicine2017

Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors.

Fakhar Ud Din, Waqar Aman, Izhar Ullah, Omer Salman Qureshi, Omer Mustapha, Shumaila Shafique, Alam Zeb

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of nanomedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 434 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
434citing papers in PubMed, 2 pooled it
36.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

434 citing papers in PubMed, 2 syntheses or guidelines pooled it, 1,506 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review

374 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 7 institutions in 1 country.

Fakhar Ud Din *Department of Pharmacy, Quaid-i-Azam University, Islamabad.
Waqar Aman *Department of Pharmacy, Kohat University of Science and Technology, Kohat.
Izhar UllahDepartment of Health and Medical Sciences, University of Poonch, Rawalakot, Azad Kashmir.
Omer Salman QureshiFaculty of Pharmacy, University of Lahore, Lahore.
Omer MustaphaFaculty of Pharmacy, Ziauddin University, Karachi.
Shumaila ShafiqueDepartment of Pharmaceutics, Faculty of Pharmaceutical Sciences, Dow University of Health Sciences, Karachi.
Alam ZebRiphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan.
Dow University of Health Sciences · PKKohat University of Science and Technology · PKQuaid-i-Azam University · PKRiphah International University · PKUniversity of Azad Jammu and Kashmir · PKUniversity of Lahore · PKZiauddin University · PK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanotechnology has recently gained increased attention for its capability to effectively diagnose and treat various tumors. Nanocarriers have been used to circumvent the problems associated with conventional antitumor drug delivery systems, including their nonspecificity, severe side effects, burst release and damaging the normal cells. Nanocarriers improve the bioavailability and therapeutic efficiency of antitumor drugs, while providing preferential accumulation at the target site. A number of nanocarriers have been developed; however, only a few of them are clinically approved for the delivery of antitumor drugs for their intended actions at the targeted sites. The present review is divided into three main parts: first part presents introduction of various nanocarriers and their relevance in the delivery of anticancer drugs, second part encompasses targeting mechanisms and surface functionalization on nanocarriers and third part covers the description of selected tumors, including breast, lungs, colorectal and pancreatic tumors, and applications of relative nanocarriers in these tumors. This review increases the understanding of tumor treatment with the promising use of nanotechnology.

Indexed as

Drug Delivery SystemsDrug CarriersHumansNanoparticlesNanotubes, CarbonNeoplasmsDrug CarriersNanotubes, Carbonbreast tumorcolorectal tumordendrimersdrug deliveryliposomeslungs tumornanocarrierspolymeric nanoparticlesprostate tumorsolid lipid nanoparticles

Identifiers

PMID29042776
PMCPMC5634382
OpenAlexW2762341360

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.